Richter Syndrome Clinical Trials

38 clinical trials for Richter Syndrome across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype — RECRUITING · PHASE2
• Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome — RECRUITING · PHASE2
• Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma — RECRUITING · PHASE1
• Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — RECRUITING · PHASE2
• Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation — RECRUITING · PHASE2
• Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation — RECRUITING · PHASE1
• CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL — RECRUITING · PHASE2
• Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome — ACTIVE_NOT_RECRUITING · PHASE2
• A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome — ACTIVE_NOT_RECRUITING · PHASE2
• Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas — COMPLETED · PHASE2
• Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial — NOT_YET_RECRUITING · PHASE3
• Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation — ACTIVE_NOT_RECRUITING · PHASE2
• Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS — ACTIVE_NOT_RECRUITING · PHASE1
• ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation — WITHDRAWN · PHASE1
• Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma — COMPLETED · PHASE1
• CHOP PLUS MOSUNETUZUMAB AS FIRST LINE IN PATIENTS WITH RICHTER´S SYNDROME: A PHASE II STUDY OF THE SPANISH GROUP OF CLL (GELLC-9-RICHTER) — TERMINATED · PHASE2
• Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation — COMPLETED · PHASE2
• Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — WITHDRAWN · PHASE2
• A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome — TERMINATED · PHASE1
• (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) — NOT_YET_RECRUITING
• Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) — COMPLETED · PHASE2
• Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients — TERMINATED · PHASE2
• BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation — COMPLETED · PHASE2
• Genomic and Proteomic Study of Richter Syndrome (CGPSR) — OTHER
• HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL — WITHDRAWN · PHASE1
• Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation — COMPLETED · PHASE1
• A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies — TERMINATED · PHASE1
• Allogeneic Stem Cell Transplant for CLL — TERMINATED · PHASE1
• Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia — COMPLETED · PHASE2
• Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers — COMPLETED · PHASE1
• Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation — WITHDRAWN · PHASE2

Refine this search